Taltz (ixekizumab) vs Idacio (adalimumab-aacf)

Taltz (ixekizumab) and Idacio (adalimumab-aacf) are both used to treat various inflammatory conditions, but they work in different ways: Taltz is an interleukin-17A (IL-17A) antagonist indicated for conditions like plaque psoriasis and psoriatic arthritis, while Idacio is a biosimilar to Humira (adalimumab) and targets tumor necrosis factor (TNF) alpha, making it suitable for a broader range of conditions including rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Taltz is typically administered every 4 weeks after initial loading doses, compared to Idacio which may be administered weekly or every other week depending on the condition. When deciding between the two, considerations include the specific condition being treated, the patient's response to previous therapies, potential side effects, and the mode of administration.

Difference between Taltz and Idacio

Metric	Taltz (ixekizumab)	Idacio (adalimumab-aacf)
Generic name	Ixekizumab	Adalimumab-aacf
Indications	Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis	Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis
Mechanism of action	Interleukin-17A antagonist	Tumor necrosis factor (TNF) blocker
Brand names	Taltz	Idacio
Administrative route	Subcutaneous injection	Subcutaneous injection
Side effects	Injection site reactions, upper respiratory tract infections, nausea, fungal infections	Injection site reactions, upper respiratory tract infections, headache, rash, gastrointestinal issues
Contraindications	Hypersensitivity to ixekizumab or any of the excipients	Hypersensitivity to adalimumab or any of its excipients, active tuberculosis or other severe infections
Drug class	Monoclonal antibody	Monoclonal antibody
Manufacturer	Eli Lilly and Company	Fresenius Kabi

Efficacy

Efficacy of Taltz (Ixekizumab) in Treating Psoriatic Arthritis

Taltz (ixekizumab) is a biologic medication approved by the FDA for the treatment of adults with active psoriatic arthritis (PsA). Ixekizumab works by targeting interleukin-17A (IL-17A), a protein that plays a role in inflammation and is found in high levels in psoriatic arthritis. Clinical trials have demonstrated that Taltz can significantly reduce the signs and symptoms of PsA, including joint pain, swelling, and stiffness. In these trials, patients treated with Taltz showed improved physical function and slowed progression of joint damage compared to placebo.

The SPIRIT-P1 and SPIRIT-P2 studies are pivotal phase 3 trials that evaluated the efficacy of Taltz in PsA patients. The results indicated that a significant proportion of patients achieved a 20% improvement in disease symptoms as measured by the American College of Rheumatology criteria (ACR20) at 24 weeks. Additionally, Taltz was shown to be effective in patients who had previously failed to respond to one or more tumor necrosis factor (TNF) inhibitors, suggesting its potential as a treatment option for patients with refractory PsA.

Efficacy of Idacio (Adalimumab-aacf) in Treating Psoriatic Arthritis

Idacio is a biosimilar to the reference product Humira (adalimumab) and is approved for the same indications, including the treatment of psoriatic arthritis. Adalimumab-aacf is a TNF inhibitor that works by blocking the action of TNF, a substance in the body that causes inflammation in the joints and skin. Clinical studies have shown that Idacio is highly similar to its reference product in terms of safety, purity, and potency. In the context of PsA, Idacio has been shown to reduce the rate of progression of joint damage, improve physical function, and decrease the signs and symptoms of the disease.

The efficacy of Idacio in psoriatic arthritis is supported by extensive clinical data from studies conducted on the reference product, Humira. Patients treated with adalimumab have demonstrated significant improvements in ACR20 response rates compared to placebo, with some patients achieving ACR50 and ACR70 responses, indicating a 50% and 70% improvement in disease symptoms, respectively. The biosimilar Idacio is expected to provide a similar clinical outcome to patients with PsA, offering an alternative treatment option with comparable efficacy.

Regulatory Agency Approvals

Taltz

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia

Idacio

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Taltz or Idacio today

If Taltz or Idacio are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Taltz

Buy Idacio

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: